Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Summit Therapeutics Inc’s current trading price is -29.66% away from its 52-week high, while its distance from the 52-week low is 198.09%. The stock’s price range over this period has fluctuated between $8.71 and $36.91. The company, operating within the financial sector, had a trading volume of approximately 1.68 million for the day, which was noticeably lower than the average daily share volume of 4.87 million over the last 3 months.
The stock price for Summit Therapeutics Inc (SMMT) currently stands at $25.96. The stock experienced a substantial increase in the last session, hitting $43.92 after starting at $26.27. The stock’s lowest price was $11.95 before closing at $24.36.
The market performance of Summit Therapeutics Inc’s stock has been harmonious in recent times. Over the last year, the company’s stock reached its highest point at $36.91 on 04/24/25, while the lowest value for the same duration was $8.71 on 07/19/24.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Summit Therapeutics Inc (SMMT) has experienced a quarterly decline of -0.64% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 19.28B and boasts a workforce of 159 employees.
Summit Therapeutics Inc: What Analysts Are Saying
As of right now, 7 analysts are rating Summit Therapeutics Inc as a BUY, 3 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 22.07, with a change in price of +3.29. Similarly, Summit Therapeutics Inc recorded 4,244,135 in trading volume during the last 100 days, posting a change of +14.27%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for SMMT stands at 0.02. Similarly, the long-term debt-to-equity ratio is also 0.01.
SMMT Stock Stochastic Average
Today, Summit Therapeutics Inc’s raw stochastic average for the past 50 days stands at 84.25%, indicating a decline from the raw stochastic average of the last 20 days, which was 93.85%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 84.02% and 83.73% respectively.
SMMT Stock Price Performance Analysis
Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. This year’s metric has recorded a Price increase of 203.67%. However, over the past six months, we’ve seen a weaker performance of 42.86%. The price of SMMT fallen by 31.26% over the last 30 days. And in the last five days, it has surged by 4.95%.
